Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
One year of adjuvant trastuzumab is considered the standard treatment for patients with HER2 positive breast cancer. However, a shorter duration of trastuzumab may be associated with reduced costs and side effects. Results from randomized trials with diverse non-inferiority margins comparing one yea...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2020-12-01
|
| coleção: | Breast |
| Assuntos: | |
| Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S0960977620301946 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|